GE's imaging agents to enable more personalized therapies for patients
NISKAYUNA, New York - September 22, 2008 -- GE Global Research, the technology development arm for the General Electric Company (NYSE: GE), announced a two-year cooperative research and development agreement with the National Cancer Institute (NCI) to accelerate the development of cutting-edge nanoparticle based imaging agents that have the potential to revolutionize the diagnosis and treatment of cancer and heart disease.